X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (131) 131
humans (116) 116
oral phosphodiesterase-4 inhibitor (83) 83
administration, oral (70) 70
double-blind (65) 65
psoriasis (59) 59
pharmacology & pharmacy (56) 56
male (54) 54
thalidomide - analogs & derivatives (41) 41
apremilast (40) 40
dermatology (40) 40
female (40) 40
animals (38) 38
phase-iii (37) 37
psoriatic arthritis (37) 37
placebo-controlled trial (36) 36
efficacy (35) 35
thalidomide - therapeutic use (32) 32
adult (31) 31
psoriasis - drug therapy (30) 30
severe plaque psoriasis (30) 30
treatment outcome (30) 30
middle aged (28) 28
rheumatology (28) 28
arthritis (27) 27
arthritis, psoriatic - drug therapy (27) 27
clinical trials (26) 26
safety (26) 26
severity of illness index (26) 26
controlled-trial (25) 25
phosphodiesterase 4 inhibitors - therapeutic use (24) 24
anti-inflammatory agents, non-steroidal - therapeutic use (23) 23
drug therapy (22) 22
inflammation (22) 22
medicine & public health (22) 22
care and treatment (21) 21
pde4 inhibitor (21) 21
randomized controlled-trial (20) 20
moderate (19) 19
obstructive pulmonary-disease (19) 19
antirheumatic agents - therapeutic use (18) 18
pulmonary disease, chronic obstructive - drug therapy (18) 18
thalidomide - administration & dosage (18) 18
thalidomide - adverse effects (18) 18
analysis (17) 17
asthma (17) 17
internal medicine (17) 17
phosphodiesterase 4 inhibitors - administration & dosage (17) 17
drug administration schedule (16) 16
copd (15) 15
dosage and administration (15) 15
double-blind method (15) 15
methotrexate (15) 15
monoclonal-antibody (15) 15
phosphodiesterase-4 inhibitor (15) 15
quality-of-life (15) 15
rheumatoid-arthritis (15) 15
roflumilast (15) 15
studies (15) 15
tumor necrosis factor-alpha - antagonists & inhibitors (15) 15
anti-inflammatory agents, non-steroidal - adverse effects (14) 14
dose-response relationship, drug (14) 14
drug therapy, combination (14) 14
necrosis-factor-alpha (14) 14
phosphodiesterase 4 inhibitors - adverse effects (14) 14
quality of life (14) 14
janus kinase inhibitor (13) 13
management (13) 13
respiratory system (13) 13
disease (12) 12
pharmacology/toxicology (12) 12
phosphodiesterase 4 inhibitors - pharmacology (12) 12
phosphodiesterase inhibitors - pharmacology (12) 12
spondyloarthritis (12) 12
toxicology (12) 12
administration, inhalation (11) 11
aged (11) 11
mice (11) 11
phosphodiesterase-4 (11) 11
psoriasis - pathology (11) 11
review (11) 11
secukinumab (11) 11
usage (11) 11
aminopyridines - administration & dosage (10) 10
benzamides - administration & dosage (10) 10
corticosteroids (10) 10
cyclopropanes - administration & dosage (10) 10
cytokines (10) 10
health aspects (10) 10
immunology (10) 10
inflammation - drug therapy (10) 10
lung diseases, obstructive (10) 10
pharmacotherapy (10) 10
phosphodiesterase inhibitors - therapeutic use (10) 10
psoriatic-arthritis (10) 10
randomized controlled trials as topic (10) 10
rats (10) 10
research (10) 10
time factors (10) 10
ustekinumab (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Pharmacology, ISSN 0007-1188, 02/2010, Volume 159, Issue 4, pp. 842 - 855
Background and purpose:  Apremilast is an orally administered phosphodiesterase-4 inhibitor, currently in phase 2 clinical studies of psoriasis and other... 
immunopharmacology | anti-inflammatory drugs | PDE inhibitor | chemokines | inflammation | skin pharmacology | anti‐inflammatory drugs | Skin pharmacology | Inflammation | Anti-inflammatory drugs | Immunopharmacology | Chemokines | TRANSCRIPTION FACTORS | DIFFERENTIAL EXPRESSION | ELEMENT-BINDING PROTEIN | NECROSIS-FACTOR-ALPHA | PERITONEAL-MACROPHAGES | PDE4 INHIBITORS | OBSTRUCTIVE PULMONARY-DISEASE | CYCLIC-AMP PHOSPHODIESTERASE | PHARMACOLOGY & PHARMACY | NF-KAPPA-B | PLAQUE-TYPE PSORIASIS | Humans | Middle Aged | Thalidomide - pharmacology | RNA, Messenger - metabolism | Zymosan - metabolism | Thalidomide - analogs & derivatives | Ultraviolet Rays | Psoriasis - pathology | Time Factors | U937 Cells | Anti-Inflammatory Agents - administration & dosage | Skin Transplantation | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cytokines - genetics | Keratinocytes - enzymology | Disease Models, Animal | Psoriasis - immunology | Leukocytes, Mononuclear - drug effects | Psoriasis - drug therapy | Administration, Oral | Anti-Inflammatory Agents - pharmacology | Thalidomide - administration & dosage | Skin - enzymology | Keratinocytes - immunology | Killer Cells, Natural - enzymology | Keratinocytes - drug effects | Lipopolysaccharides - pharmacology | Killer Cells, Natural - drug effects | Mice | Transplantation, Heterologous | Dose-Response Relationship, Drug | Psoriasis - genetics | Enterotoxins - immunology | Leukocytes, Mononuclear - immunology | Inflammation Mediators - metabolism | Phosphodiesterase 4 Inhibitors | Killer Cells, Natural - immunology | Adult | Skin - pathology | Skin - immunology | Severity of Illness Index | Cytokines - metabolism | Phosphodiesterase Inhibitors - pharmacology | Mice, SCID | Gene Expression Regulation - drug effects | Phosphodiesterase Inhibitors - administration & dosage | Animals | Skin - radiation effects | Leukocytes, Mononuclear - enzymology | Cell Proliferation - drug effects | Psoriasis - enzymology | Skin - drug effects | Psoriasis | Tumor necrosis factor-TNF | Rodents | Research Papers
Journal Article
Journal Article
International Journal of COPD, ISSN 1176-9106, 06/2015, Volume 10, pp. 1123 - 1128
Background: A new approach to the treatment of COPD includes controlling inflammation because of its important role in exacerbation of the disease. Recently,... 
Phosphodiesterase-4 inhibitors | Roflumilast | COPD | roflumilast | OBSTRUCTIVE PULMONARY-DISEASE | NEUTROPHIL | EFFICACY | RESPIRATORY SYSTEM | AIRWAY INFLAMMATION | LUNG-FUNCTION | EXACERBATIONS | MARKERS | phosphodiesterase-4 inhibitors | Spirometry | Humans | Pulmonary Disease, Chronic Obstructive - physiopathology | Recovery of Function | Lung - enzymology | Forced Expiratory Volume | Greece | Benzamides - administration & dosage | Flow Cytometry | Tiotropium Bromide - administration & dosage | Cyclopropanes - administration & dosage | Time Factors | Phosphodiesterase 4 Inhibitors - administration & dosage | Anti-Inflammatory Agents - administration & dosage | Drug Therapy, Combination | Aminopyridines - administration & dosage | Pulmonary Disease, Chronic Obstructive - diagnosis | Phagocytosis - drug effects | Drug Administration Schedule | Administration, Oral | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Salmeterol Xinafoate - administration & dosage | Pulmonary Disease, Chronic Obstructive - enzymology | Muscarinic Antagonists - administration & dosage | Vital Capacity | Pilot Projects | Fluticasone - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Adrenal Cortex Hormones - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Drug therapy | Health aspects | Patient outcomes | Phagocytosis
Journal Article
Journal Article
Journal Article
Clinical and Experimental Dermatology, ISSN 0307-6938, 06/2017, Volume 42, Issue 4, pp. 471 - 473
Click here for the corresponding questions to this CME article. 
TRIALS | ORAL PHOSPHODIESTERASE-4 INHIBITOR | PSORIASIS | DERMATOLOGY | Pustulosis
Journal Article
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 2002, Volume 12, Issue 11, pp. 1457 - 1461
Journal Article
Arthritis & Rheumatology, ISSN 2326-5191, 05/2016, Volume 68, Issue 5, pp. 1060 - 1071
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 4, pp. e34 - e46
Journal Article
Journal Article